Therapeutic Advances in Psychopharmacology最新文献

{"title":"Ketamine-assisted therapy within a community of practice: a novel approach to disordered eating.","authors":"Lara Jeletzky, Shannon Dames, Pamela Kryskow, Vivian W L Tsang","doi":"10.1177/20451253251356980","DOIUrl":"10.1177/20451253251356980","url":null,"abstract":"","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251356980"},"PeriodicalIF":3.4,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis.","authors":"Yanyan Jia, Zifeng Ye, Fude Yang, Jiabao Chai, Haiting Xu, Jingming Yang, Weiye Liang, Lili Wu","doi":"10.1177/20451253251342628","DOIUrl":"10.1177/20451253251342628","url":null,"abstract":"<p><strong>Background: </strong>Post-traumatic stress disorder (PTSD) is a prevalent mental illness with a high disability rate. The neurobiological abnormalities in PTSD suggest that drug therapy may have certain therapeutic effects. According to the recommendations of clinical guidelines for PTSD, the current clinical preference is for selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs). Nevertheless, the efficacy of other types of drugs remains uncertain, which impacts the selection of personalized treatment for patients.</p><p><strong>Objectives: </strong>The aim of this meta-analysis was to assess the efficacy and acceptability of drugs with different pharmacological mechanisms in alleviating PTSD symptoms by comparing the response rates and dropout rates of different drug treatment groups in randomized clinical trials.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Methods: </strong>We searched and analyzed 52 reports that described the efficacy and acceptability of medication for PTSD. Among these, 49 trials used the dropout rate as an acceptability indicator, and 52 trials used the response rate as an efficacy indicator.</p><p><strong>Results: </strong>In the 49 trials with the dropout rate as the indicator, the dropout rate was 29% (95% confidence interval, 0.26-0.33; <i>n</i> = 3870). In the 52 trials with the response rate as the indicator, the response rate was 39% (95% confidence interval, 0.33-0.45; <i>n</i> = 3808). After drug treatment, the core symptoms of PTSD were significantly improved. This meta-analysis indicated that there was no significant difference between antidepressants and antipsychotics in improving clinical symptoms and acceptability. However, antidepressants may have a slight advantage in efficacy, although with a higher dropout rate.</p><p><strong>Conclusion: </strong>Drug treatment is an effective rehabilitation method for PTSD patients, and individualized drug management should be considered.</p><p><strong>Trial registration: </strong>This systematic evaluation scheme has been registered with PROSPERO (protocol ID: CRD42023462662).</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251342628"},"PeriodicalIF":3.4,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12171264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.","authors":"Nadav Liam Modlin, Victoria Williamson, Carolina Maggio, Joanne Stubley, Namik Kirlic, Anthony Cleare, James Rucker","doi":"10.1177/20451253251342319","DOIUrl":"10.1177/20451253251342319","url":null,"abstract":"<p><p>Post-traumatic stress disorder (PTSD) and associated trauma and stressor-related disorders are common and debilitating, presenting significant treatment challenges due to their complex interplay of biological, cognitive, affective, somatic and social factors. Current treatments, while advancing and effective, yield limited efficacy for many individuals, underscoring the need for novel therapeutic approaches. This review explores the multifaceted nature of PTSD, emphasising its intricate predisposing and maintaining factors and explores the potential of psilocybin, a classical psychedelic, as a therapeutic agent. This review synthesises recent literature on the safety, efficacy and proposed mechanisms of action and change of psychedelic therapies for psychiatric conditions associated with traumatic stress, including treatment-resistant depression, end-of-life anxiety and anorexia nervosa. Correspondingly, it proposes a conceptual framework for psilocybin treatment in PTSD, framing the condition as a complex, maladaptive interpretive framework that is both predetermined and over-determined. A clinical narrative illustrates how psilocybin's unique psychopharmacological properties and catalysed subjective effects may facilitate therapeutic progress by disrupting this rigid and restricting framework. Finally, we offer recommendations for the safe administration of psilocybin for traumatised patients in medical research settings, emphasising the importance of rigorous and trauma-informed protocols and comprehensive patient care.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251342319"},"PeriodicalIF":3.4,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug utilization in geriatric psychiatric patients in the emergency department-a cohort study under real-world conditions.","authors":"Martin Schulze Westhoff, Sophie Bannasch, Johannes Heck, Stefan Bleich, Sebastian Schröder, Adrian Groh","doi":"10.1177/20451253251339373","DOIUrl":"10.1177/20451253251339373","url":null,"abstract":"<p><strong>Background: </strong>Psychiatric emergencies include agitation, substance-related (e.g., withdrawal) symptoms, and suicidal as well as self-harming behavior and require interdisciplinary management. Drug treatment of geriatric patients in emergency situations may be complicated by adverse drug reactions (ADRs).</p><p><strong>Objectives: </strong>This study aimed to investigate prescriptions of potentially inappropriate medications (PIMs) and potential drug-drug interactions (DDIs) in the context of geriatric psychiatric emergencies in the emergency department (ED).</p><p><strong>Design: </strong>Retrospective single-center study.</p><p><strong>Methods: </strong>The medication lists of 87 consecutively acquired geriatric patient cases receiving pharmacological treatment between January 2018 and December 2022 in a psychiatric emergency department were analyzed. Herein, utilizing the PRISCUS 2.0 list and the Fit fOR The Aged (FORTA) classification, prescriptions of PIMs were assessed, and DDIs were classified with the aid of the drug interaction program AiDKlinik® (Arzneimittel-Informations-Dienste, Dosing GmbH, Heidelberg, Germany).</p><p><strong>Results: </strong>A total of 94 drugs were administered during treatment in the ED. The total number of drugs per patient was on average 5.9 1 (median: 5; interquartile range: 4) hereafter. 77.7% of the newly prescribed drugs were PIMs according to the PRISCUS 2.0 list, while 18.1% were designated as therapeutic alternatives to PIMs. 70.2% and 22.3% of the newly recommended drugs were FORTA category C and D drugs, respectively. An average of 0.8 (median: 0; interquartile range: 1) potential DDIs existed before psychiatric ED treatment, and 0.9 (median: 0; interquartile range: 2) potential DDIs thereafter (<i>p</i> = 0.002). Coercive measures-such as administration of medication against the patient's will-were rarely required in the study population.</p><p><strong>Conclusion: </strong>The majority of all drug prescriptions for the treatment of geriatric psychiatric emergencies were categorized as PIMs according to the PRISCUS 2.0 list and the FORTA classification. However, it should be noted that these PIM classification systems were not specifically designed for geriatric psychiatric settings. The number of potential DDIs was significantly higher after drug administration in the ED than before, which should prompt the monitoring of certain clinical parameters in the further course of treatment.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251339373"},"PeriodicalIF":3.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The missing link? Pharmacists' perspectives on discontinuation of long-term antidepressants: a qualitative study.","authors":"Ellen Van Leeuwen, Els Mehuys, Chris F Johnson, An-Sofie De Keyzer, Koen Boussery, Thierry Christiaens","doi":"10.1177/20451253251333977","DOIUrl":"https://doi.org/10.1177/20451253251333977","url":null,"abstract":"<p><strong>Background: </strong>Long-term use of antidepressant drugs is widespread despite guidelines recommending limited duration. General practitioners (GPs) play a central role in reviewing and discontinuing antidepressants, although they hesitate to initiate a discussion about the long-term use. The potential role of pharmacists in this process is underexplored, despite their pharmaceutical expertise and accessibility.</p><p><strong>Objectives: </strong>To explore community pharmacists' perspectives on the discontinuation of long-term use of antidepressants, and the barriers and facilitators to their involvement in this process.</p><p><strong>Design: </strong>Qualitative study.</p><p><strong>Methods: </strong>Semi-structured interviews were conducted with 14 Belgian community pharmacists until data saturation. Interviews were recorded, transcribed, and thematically analyzed.</p><p><strong>Results: </strong>Four themes emerged. (1) \"Antidepressants at the pharmacy: a persistent taboo\" showed pharmacists' hesitancy to initiate discontinuation discussions due to societal stigma and fear of being perceived as nosy. (2) \"Balancing risks vs benefits\" highlights that pharmacists were primarily concerned about relapse in stable patients but recognized that a patient request from a patient experiencing side effects may facilitate discontinuation. (3) \"Is this my role?,\" pharmacists viewed GPs as the primary decision-makers in discontinuation, limiting their role to supporting GP treatment decisions. Key facilitators for discontinuation included a GP's decision to stop and a motivated patient. Regular reviews by the pharmacist could also facilitate the discontinuation process. (4) Optimizing pharmacists' role' with a strong need for GP collaboration, and acknowledging a need to optimize knowledge and skills to support antidepressant discontinuation.</p><p><strong>Conclusion: </strong>Our study reveals that pharmacists viewed GPs as pivotal in the discontinuation process, as they make the decisions, while they see their role as supportive, following the doctor's decision. However, they faced significant barriers to discontinuing long-term antidepressants, including fear of relapse, societal taboo, and unclear responsibilities. More education, confidence building, and better collaboration with GPs could empower pharmacists to play a proactive role, improving the antidepressant discontinuation process.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251333977"},"PeriodicalIF":3.4,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reasons for discontinuing and restarting lithium multiple times: a case-register study based on the South London and Maudsley NHS Foundation Trust Clinical Record Interactive Search system.","authors":"Petra Truedson, Kalliopi Vallianatou, Michael Ott, Martin Maripuu, Krister Lindmark, David M Taylor, Ursula Werneke","doi":"10.1177/20451253251332275","DOIUrl":"https://doi.org/10.1177/20451253251332275","url":null,"abstract":"<p><strong>Background: </strong>Despite the therapeutic benefits, non-adherence to lithium is common. One recent study showed that most patients discontinue lithium due to adverse effects. Little is known about individuals starting and discontinuing lithium repeatedly.</p><p><strong>Objectives: </strong>We aimed to determine reasons for discontinuing and restarting lithium multiple times in patients with bipolar or schizoaffective disorder.</p><p><strong>Design: </strong>Retrospective cohort study based on psychiatric case records of the SLaM Biomedical Research Centre Case Register (SLaM BRC case register).</p><p><strong>Method: </strong>Anonymised clinical data were extracted via the Clinical Record Interactive Search (CRIS) application. Patients with at least three events of lithium discontinuation between 2012 and 2022 were included.</p><p><strong>Results: </strong>Of 2888 eligible patients, 123 patients had discontinued lithium on at least three occasions. Psychiatric reasons, such as suspected lack of insight, feeling subjectively well or disagreeing with diagnosis, were the most common reasons for lithium discontinuations. They accounted for 77.2% of cases in the first event of discontinuation, 73.2% in the second and 72.3% in the third event. Adverse physical effects accounted for 19.5% of cases in the first event of discontinuation, 25.2% in the second and 26.0% in the third event. Relapse into the underlying affective disorder accounted for 83.7% each of reinstatements in the first and second events and 82.1% in the third event.</p><p><strong>Discussion: </strong>In our sample, lithium was discontinued due to adverse effects in only a minority of patients. In most cases, the reasons for lithium discontinuation were considered psychiatric. Lithium was mainly restarted due to relapse. This warrants a better understanding of the reasons for repeatedly discontinuing lithium and the best way to promote lithium adherence to prevent a perpetual cycle of remitting when on lithium and relapsing when off lithium.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251332275"},"PeriodicalIF":3.4,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation on the factors associated with maintenance of paliperidone long-acting injection in the real-world treatment of patients with schizophrenia.","authors":"Nuree Kang, Ae Jeong Jo, Sung Woo Joo, Jung Sun Lee, Kyu Young Lee, Yong Sik Kim, Jae Hoon Jeong, Jeong Hoon Lee, Joongyub Lee, Se Hyun Kim","doi":"10.1177/20451253251333987","DOIUrl":"https://doi.org/10.1177/20451253251333987","url":null,"abstract":"<p><strong>Background: </strong>Long-acting injectable (LAI) antipsychotics have been shown to improve adherence and clinical outcomes in schizophrenia treatment. However, issues with compliance and early discontinuation of LAIs remain a significant challenge in real-world settings. Understanding the factors influencing successful initiation and maintenance is essential to maximize their clinical benefits.</p><p><strong>Objectives: </strong>This study aimed to investigate factors associated with the maintenance of paliperidone LAI (PLAI) during the first year of treatment in a real-world clinical setting, focusing on initiation practices and baseline clinical factors.</p><p><strong>Design: </strong>This was a non-interventional, retrospective observational study conducted at three hospitals in South Korea. Data were collected from electronic medical records from January 2010 to January 2023.</p><p><strong>Methods: </strong>This study included 664 patients who initiated PLAI treatment. Kaplan-Meier survival analysis and multivariate Cox proportional hazards models were used to evaluate clinical and demographic factors influencing the 1-year discontinuation rate.</p><p><strong>Results: </strong>The 1-year discontinuation rate was 51.5% (342/664), with most discontinuations occurring in the early phase of treatment. Factors significantly associated with a lower risk of discontinuation included initiating PLAI with the standard starting dose of 150 mg (hazards ratio (HR) 0.766, <i>p</i> = 0.021), concurrent use of antipsychotics at baseline (HR 0.630, <i>p</i> = 0.019), a higher dose of concurrent antipsychotics (HR 0.985, <i>p</i> = 0.005), and outpatient initiation (HR 0.671, <i>p</i> < 0.001). Baseline clozapine use was associated with a lower risk of treatment discontinuation (HR 0.755, <i>p</i> = 0.096). A predictive model incorporating these factors demonstrated moderate ability to predict 1-year discontinuation (area under the curve (AUC) = 0.61).</p><p><strong>Conclusion: </strong>The findings highlight the importance of adhering to the standard dosing regimen for PLAI initiation and its potential as an augmentation agent in combination with other antipsychotics. Initiating PLAI in an outpatient setting and addressing adherence challenges early in treatment may enhance long-term treatment continuity in patients with schizophrenia.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251333987"},"PeriodicalIF":3.4,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between resilience and mental health among COVID-19 bereaved people: the mediating role of dual process coping.","authors":"Liping Wu, Siying Chen, Suqin Tang","doi":"10.1177/20451253251328607","DOIUrl":"10.1177/20451253251328607","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;People bereaved due to COVID-19 may face mental health challenges and posttraumatic growth opportunities. Resilience, as an inherent trait or ability, may protect the bereaved from developing mental health problems and facilitate growth. The Dual Process Model (DPM) is an important framework for understanding adaptation after bereavement. However, little is known about whether resilience could help with adjusting to COVID-19 bereavement and whether dual process coping plays a part in the relationship between resilience and mental health among COVID-19 bereaved individuals.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;We aim to examine the relationship between resilience and symptoms of prolonged grief, posttraumatic stress, anxiety, depression, and posttraumatic growth following COVID-19 bereavement, and to investigate the role of dual process coping, which includes loss-oriented (LO) coping, restoration-oriented (RO) coping, and oscillation between LO coping and RO coping in this relationship.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;This is an online cross-sectional survey.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Method: &lt;/strong&gt;A total of 408 Chinese participants who lost a close person due to COVID-19 participated in the study from September to October 2020. Demographic and loss-related information was collected. Resilience, dual process coping, symptoms of prolonged grief, posttraumatic stress, anxiety, depression, and posttraumatic growth were measured. Correlation analyses and mediation analyses were conducted to analyze the data.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Resilience was negatively correlated with anxiety and depressive symptoms and positively correlated with posttraumatic growth. In the relationship between LO coping, RO coping, oscillation, and mental health, LO coping was positively associated with prolonged grief, posttraumatic stress, anxiety, and depressive symptoms, as well as posttraumatic growth; RO coping was negatively associated with prolonged grief symptoms and posttraumatic growth, and positively associated with anxiety and depressive symptoms; oscillation was negatively associated with prolonged grief, posttraumatic stress, anxiety, and depressive symptoms. In addition, mediation analysis showed that oscillation mediated the relationship between resilience and anxiety and depressive symptoms, and RO coping mediated the relationship between resilience and depressive symptoms and posttraumatic growth.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Our findings indicate that among individuals who have experienced bereavement due to COVID-19, RO coping serves a protective role in the relationship between resilience and depressive symptoms and a facilitative role in the relationship between resilience and posttraumatic growth. Additionally, oscillation plays a protective role in the association between resilience and symptoms of anxiety and depression. Professionals should consider the bereaved individuals' resilience, LO coping, RO coping, and osci","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251328607"},"PeriodicalIF":3.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased citalopram concentration caused by enzyme induction effect of rifampin: a case report.","authors":"Jiajia Liu, Jinmeng Li, Ren Zheng, Ruoying Zhang","doi":"10.1177/20451253251328582","DOIUrl":"10.1177/20451253251328582","url":null,"abstract":"<p><p>Citalopram is a selective serotonin reuptake inhibitor used to treat depression and various anxiety disorders, which is mainly metabolized by the P450 (CYP) enzyme. Rifampin is a rifamycin with bactericidal activity against <i>Mycobacterium tuberculosis</i>. Rifampin significantly induces the P450 (CYP) enzyme system, which makes it susceptible to potential drug interactions with other medications. However, there have been few reports on the possible interaction between rifampin and citalopram. We report a 76-year-old patient who had been taking citalopram 20 mg daily for long-term treatment of depression. After 2 months of rifampin treatment for tuberculosis, the patient presented with intractable depressive symptoms, insomnia, and a profound sense of hopelessness. The trough plasma concentration of citalopram was monitored, which was 8.19 ng/mL, and failed to reach the guideline-recommended effective therapeutic range (50-110 ng/mL). Based on the therapeutic drug monitoring results of citalopram, the dosage of citalopram was adjusted to 40 mg daily, resulting in a significant improvement in depressive symptoms. This case provides further evidence of a clinically significant interaction that may occur between rifampin and citalopram.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251328582"},"PeriodicalIF":3.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolution of long-acting antipsychotic treatments.","authors":"Sofia Pappa, Robin Emsley","doi":"10.1177/20451253241305610","DOIUrl":"10.1177/20451253241305610","url":null,"abstract":"","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"14 ","pages":"20451253241305610"},"PeriodicalIF":3.4,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}